top of page
gradientForSurfBreak.png

Item List

Oct 21, 2024
Businesswire
Epitel Expands AI Portfolio With A Fourth FDA 510(k) Clearance for REMI

Epitel, a leader in AI for patient-focused brain health technologies, announced today it received U.S. Food and Drug Administration (FDA) 510(k) clearance for REMI Vigilenz™ AI For Bedside Notifications. REMI Vigilenz AI For Bedside Notifications conducts an automated analysis of EEG data collected by the REMI™ wireless wearable EEG System in near real-time. Notifications occur when the algorithm recognizes seizure characteristics within a section of EEG.

Recent Posts

Portfolio Company

Carlsmed.png

Iterative Health Closes $77 Million Series C to Accelerate the Future of Clinica ...

Businesswire

Apr 30, 2026

Portfolio Company

Carlsmed.png

Strados Labs Acquires Clinical Trial Business of NuvoAir, Delivering Full-Spectr ...

BioSpace

Apr 16, 2026

Portfolio Company

Carlsmed.png

The most innovative healthcare companies of 2026 ...

Fast Company

Mar 24, 2026

surf break copy_edited_edited.jpg
surbreak-19.png
WM360_logo-18.png
bottom of page